ULTRAGENYX PHARMACEUTICAL IN (RARE)
US90400D1081 - Common Stock
Overall RARE gets a fundamental rating of 4 out of 10. We evaluated RARE against 587 industry peers in the Biotechnology industry. The financial health of RARE is average, but there are quite some concerns on its profitability. RARE shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year RARE has reported negative net income.
RARE had a negative operating cash flow in the past year.
RARE had negative earnings in each of the past 5 years.
RARE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -46.92%, RARE is in line with its industry, outperforming 51.28% of the companies in the same industry.
RARE's Return On Equity of -437.23% is on the low side compared to the rest of the industry. RARE is outperformed by 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.92% | ||
| ROE | -437.23% | ||
| ROIC | N/A |
ROA(3y)-38.76%
ROA(5y)-32.47%
ROE(3y)-156.72%
ROE(5y)-109.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 88.59%, RARE belongs to the top of the industry, outperforming 92.14% of the companies in the same industry.
RARE's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for RARE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.59% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.86%
GM growth 5Y-1.71%
2. Health
2.1 Basic Checks
RARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RARE has been increased compared to 1 year ago.
The number of shares outstanding for RARE has been increased compared to 5 years ago.
RARE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
RARE has an Altman-Z score of -2.80. This is a bad value and indicates that RARE is not financially healthy and even has some risk of bankruptcy.
RARE has a Altman-Z score (-2.80) which is in line with its industry peers.
RARE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.8 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
A Current Ratio of 2.43 indicates that RARE has no problem at all paying its short term obligations.
With a Current ratio value of 2.43, RARE is not doing good in the industry: 72.99% of the companies in the same industry are doing better.
A Quick Ratio of 2.28 indicates that RARE has no problem at all paying its short term obligations.
The Quick ratio of RARE (2.28) is worse than 72.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.43 | ||
| Quick Ratio | 2.28 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 21.66% over the past year.
The Revenue has grown by 15.33% in the past year. This is quite good.
Measured over the past years, RARE shows a very strong growth in Revenue. The Revenue has been growing by 53.17% on average per year.
EPS 1Y (TTM)21.66%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q12.88%
Revenue 1Y (TTM)15.33%
Revenue growth 3Y17.02%
Revenue growth 5Y53.17%
Revenue growth Q2Q8.29%
3.2 Future
Based on estimates for the next years, RARE will show a very strong growth in Earnings Per Share. The EPS will grow by 20.27% on average per year.
RARE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.59% yearly.
EPS Next Y21.19%
EPS Next 2Y18.03%
EPS Next 3Y19.1%
EPS Next 5Y20.27%
Revenue Next Year19.7%
Revenue Next 2Y22.74%
Revenue Next 3Y26.32%
Revenue Next 5Y37.59%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RARE. In the last year negative earnings were reported.
Also next year RARE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as RARE's earnings are expected to grow with 19.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.03%
EPS Next 3Y19.1%
5. Dividend
5.1 Amount
No dividends for RARE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ULTRAGENYX PHARMACEUTICAL IN
NASDAQ:RARE (5/17/2024, 7:22:41 PM)
After market: 41.87 0 (0%)41.87
-0.74 (-1.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.48B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.92% | ||
| ROE | -437.23% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.59% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.43 | ||
| Quick Ratio | 2.28 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)21.66%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y21.19%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)15.33%
Revenue growth 3Y17.02%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y